For your practice
Compounded medication sourcing for weight-management clinics
A weight-management clinic is the one practice type on this site whose menu is decided mainly by federal doctrine rather than by its own state’s pharmacy rule. Two facts about the approved product decide it — whether one exists at the same, similar or easily substitutable strength usable by the same route, and whether it sits on FDA’s shortage list. Both are answered per substance, both carry a date, and both move.
Why is this category different?
Because the question that decides your menu is not a state question.
For most clinic types the binding constraint is a state pharmacy rule about non-patient-specific supply, and the answer is stable for years at a time. Here the binding constraint is a federal doctrine that applies identically in every state and changes on FDA’s schedule rather than a legislature’s. A supplier can be correctly licensed everywhere you operate and still be unable to supply a given preparation, because eligibility attaches to the substance and its approved counterpart rather than to the transaction.
That is why a clinic in this category should read its supplier’s answer with a date attached to it. An undated answer about eligibility here is not reassurance; it is an answer to a question that has since been asked again.
What is the copy rule, exactly?
It asks two things about the approved product, not about yours.
FDA’s current statement of the test asks whether a commercially available drug product contains the same active pharmaceutical ingredient, at a strength that is the same, similar or easily substitutable; and whether that commercially available product can be used by the route of administration prescribed for the compounded one. Where both hold, the compounded product is treated as essentially a copy.
There is one route through it, and it belongs to the prescriber rather than the pharmacy: the rule does not apply where a prescriber determines and documents that the compounded product contains a change producing a significant difference from the commercially available product for an identified individual patient. That is a per-patient determination recorded in a chart, not a formulary-level policy, and a supplier cannot make it for you.
Does adding a second ingredient avoid it?
No, and this is the most consequential misreading in the category.
FDA’s own published illustration of a product it may consider essentially a copy is itself a two-active-ingredient combination, where the strengths of both actives sit within ten percent of the strengths of the respective commercially available products. The agency chose a combination as the example of the problem, so a combination cannot be presented as the answer to it.
If a supplier offers a combination as the reason a preparation is permissible, that is the point at which to ask for the citation. There is a separate and narrower point about frequency: FDA has stated it does not intend to take action against a compounder for compounding a product that is essentially a copy regularly or in inordinate amounts where the compounder fills four or fewer prescriptions of that compounded product in a calendar month. That is an enforcement position about volume, not an eligibility rule, and it does not convert a copy into something else.
What does the shortage list actually do?
Two different things to two different kinds of supplier, and conflating them is how a clinic ends up with a supply that stops without warning.
For a state-licensed 503A pharmacy, a drug on FDA’s shortage list is not treated as commercially available, so the copy restriction is switched off for as long as it stays listed. For a facility registered with FDA as an outsourcing facility under section 503B, shortage status is one of only two lawful gateways to compounding from a bulk substance — the other being the 503B bulk drug substances list — and the condition requires the drug to be on the shortage list at the time of compounding, distribution and dispensing. The two gateways are independent: a proposal to change one says nothing about the other.
When a shortage ends, that route closes. FDA has said it may act where an outsourcing facility continues to fill new orders after the approved drug is removed from the shortage list, or continues filling existing orders more than sixty days after removal.
So what is the status today?
Per substance, and dated — which is the only honest form the answer takes.
Shortage status is recorded in FDA’s live database by presentation and by labeller, and substances in this category do not move together. On 29 August 2026, one substance commonly compounded for this category carried current shortage records while two others carried none at all — which means the route that is open for one is closed for the others on the same day, at the same pharmacy, for the same clinic.
Because that answer expires, it lives on a dated page rather than in prose here. The compounding status tracker carries the per-substance records with the date each was last checked, and the doctrine behind them is set out in full at essentially a copy of a commercially available drug.
What still comes from your state?
Everything about holding stock, which the federal doctrine says nothing about.
Whether a pharmacy in your state may supply non-patient-specific stock to a practice at all is a separate question with a separate answer, and it is where the entity that signs your purchase order starts to matter — Florida, for one, requires a health care clinic establishment permit where the purchasing party is a business entity with a federal employer tax identification number rather than a practitioner buying under their own licence. Georgia prohibits non-patient-specific office-use distribution for human practitioners outright while leaving outsourcing facilities untouched, and Illinois allows it for non-sterile preparations only.
The rule text for each state we have read is in the state-by-state office-use guide, and the transaction itself is walked through at how to place an office-use order.
What to bring when you apply
Three answers do most of the work here, and one of them is a habit rather than a fact.
The substances you want quoted, by active ingredient, strength and route — because eligibility turns on exactly those three things about the approved counterpart. The prescriber who will sign, since the significant-difference determination is theirs to make and to document per patient. And a standing expectation that eligibility answers carry a date: ask when the status was last checked against FDA’s own records, and treat an undated answer as no answer.
The rest of the practice types are indexed at sourcing by practice type. If you want a dated eligibility read against your own list before committing, you can apply for an account.